Singer Eric A, Golijanin Dragan J, Miyamoto Hiroshi, Messing Edward M
Department of Urology, University of Rochester Medical Center, Rochester, NY 14642, USA.
Expert Opin Pharmacother. 2008 Feb;9(2):211-28. doi: 10.1517/14656566.9.2.211.
Androgen deprivation continues to play a crucial role in the treatment of advanced and metastatic prostate cancer. In the 65 years since its use was first described, urologists and medical oncologists have developed new and innovative ways to manipulate the hypothalamic-pituitary-gonadal axis with the goal of alleviating symptoms and prolonging the life of men with prostate cancer. Despite the successes that androgen deprivation therapy has brought, each method and regimen possesses unique benefits and burdens, of which the clinician and patient must be cognizant. This review discusses the first-line androgen deprivation methods and regimens presently in use with special attention paid to their side effects and the management of them, as well as the question of when to initiate androgen deprivation therapy.
雄激素剥夺疗法在晚期和转移性前列腺癌的治疗中仍然发挥着关键作用。自首次描述其应用的65年来，泌尿外科医生和医学肿瘤学家开发了新的、创新的方法来调控下丘脑-垂体-性腺轴，目的是缓解症状并延长前列腺癌患者的生命。尽管雄激素剥夺疗法取得了成功，但每种方法和方案都有其独特的益处和负担，临床医生和患者必须对此有所认识。本综述讨论了目前使用的一线雄激素剥夺方法和方案，特别关注其副作用及其管理，以及何时开始雄激素剥夺治疗的问题。
